CryoHoldco has announced the acquisition of Criocord, a cord blood bank and cell therapy institute in Perù, for an undisclosed sum. CryoHoldco already owns the cord blood market leaders in Mexico and Colombia and now controls an important asset in Peru. A portfolio company of ACON investments, CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the largest cord blood banks worldwide. [Read more…]
NurOwn® – BrainStorm Signs Dana-Farber as Second Manufacturing Site in U.S.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has contracted with the Cell Manipulation Core Facility at Dana-Farber Cancer Institute to manufacture NurOwn® for the company’s ongoing multi-dose Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Dana-Farber will be the second U.S. manufacturing site to supply NurOwn for BrainStorm Cell Therapeutics’ ongoing trial. [Read more…]
Bio-Techne Acquires Exosome Diagnostics for $250M Cash Plus Milestones
On June 25, 2018, Bio-Techne announced it is acquiring Exosome Diagnostics for $250 million in cash and up to $325 million for achieving certain milestones. As exosome therapeutics and diagnostics have multiplied in number, a number of investors have placed big bets on this rapidly growing marketplace.
Exosomes are small vesicles ranging from 30-100nm in size that are secreted by nearly all cell types. They facilitate a range of important cellular functions, including facilitating intercellular communication. [Read more…]
Cellerant Therapeutics Awarded 20th RMAT in U.S.
On July 2nd, 2018, Cellerant Therapeutics was awarded a Regenerative Medicine Advanced Therapy (RMAT) designation for romyelocel-L (human myeloid progenitor cells) by the U.S. FDA. The treatment is used for the “prevention of serious bacterial and fungal infections in patients with de novo acute myeloid leukemia (AML) undergoing induction chemotherapy.”
Cellerant RMAT Designation
Romyelocel-Â is a universal, off-the-shelf cell therapy, because it does not require HLA matching between patient and donor. Neutropenia is a major side effect of myelosuppressive chemotherapies, including induction therapy. This can endanger patients by placing them at risk for life-threatening infections.
According to Ram Mandalam, President and CEO of Cellerant, “Receiving RMAT designation for romyelocel-L is an important milestone and recognition by the FDA of the potential of romyelocel-L to serve this unmet medical need.” [Read more…]
Eppendorf introduces first ready-to-use, synthetic cell cultureware for iPSC and MSC stem cells
Hamburg, June 2018Â –Â Since the groundbreaking discovery of human induced pluripotent stem cells (hiPSCs) by Shinya Yamanaka in 2006, the use of pluripotent stem cells (PSCs) has expeÂrienced a boom. Due to their extensive in vitro self-renewal properties and their ability to differentiate into many different cell types, PSCs, and especially hiPSCs, offer exciting promises in a wide range of cell appliÂcations including regenerative medicine. [Read more…]
- « Previous Page
- 1
- …
- 233
- 234
- 235
- 236
- 237
- …
- 338
- Next Page »